XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (13,986,000) $ (15,612,000)
Adjustments to reconcile net loss to cash used in operating activities:    
Change in fair value of common stock warrant and option liabilities (6,544,000) (3,209,000)
Change in fair value of contingent consideration 0 (70,000)
Issuance and offering costs allocated to liability classified options 430,000 314,000
Valuation loss on March 2023 PIPE 6,076,000 0
Depreciation 287,000 439,000
Amortization of intangible assets 0 40,000
Lease amortization 697,000 884,000
Impairment of intangible assets 0 404,000
Gain on disposal of equipment (40,000) (314,000)
Stock-based compensation 717,000 1,106,000
Bad debt expense 20,000 60,000
Gain on sale of Verdeca 0 (1,138,000)
Write-down of inventories 444,000 2,471,000
Impairment of property and equipment 0 530,000
Impairment of ROU asset 113,000 0
Changes in operating assets and liabilities:    
Accounts receivable and other receivables 184,000 592,000
Inventories (2,419,000) 1,118,000
Prepaid expenses and other current assets 1,000 91,000
Other noncurrent assets 2,000 16,000
Accounts payable and accrued expenses (522,000) (757,000)
Amounts due to related parties 10,000 (16,000)
Other current liabilities 0 6,000
Operating lease payments (764,000) (932,000)
Net cash used in operating activities (15,294,000) (13,977,000)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sale of property and equipment 115,000 920,000
Proceeds from sale of Verdeca - earn-out received 569,000 569,000
Proceeds from sale of investments 2,502,000 0
Purchases of property and equipment (5,000) (72,000)
Purchases of investments (7,525,000) 0
Net cash (used in) provided by investing activities (4,344,000) 1,417,000
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from ESPP purchases 12,000 7,000
Net cash provided by financing activities 5,512,000 4,519,000
Net decrease in cash and cash equivalents (14,126,000) (8,041,000)
Cash and cash equivalents - beginning of period 20,644,000 28,685,000
Cash and cash equivalents - end of period 6,518,000 20,644,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Cash paid for interest 0 1,000
NONCASH TRANSACTIONS:    
Right of use assets obtained in exchange for new operating lease liabilities 0 114,000
Proceeds from sale of property and equipment in accounts receivable and other receivables 8,000 19,000
Proceeds from sale of Verdeca in accounts receivable and other receivables 0 569,000
Accounting Standards Update 2020-06 [Member]    
NONCASH TRANSACTIONS:    
Common stock warrant liabilities reclassified to equity upon adoption of ASU 2020-06 0 3,392,000
August 2022 Offering [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE 0 5,000,000
Payments of offering costs relating to March 2023 PIPE 0 (488,000)
August 2022 RDO Securities Purchase Agreement [Member]    
NONCASH TRANSACTIONS:    
Common stock options issued to placement agent and included in offering costs 0 191,000
March 2023 PIPE [Member]    
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE 5,997,000 0
Payments of offering costs relating to March 2023 PIPE (497,000) 0
NONCASH TRANSACTIONS:    
Common stock options issued to placement agent and included in offering costs 212,000 0
Warrant and option modifications included in Valuation loss on March 2023 PIPE $ 404,000 $ 0